FORMULIERUNGEN VON BENDAMUSTIN

Patent europeic · EP4360621 · En vigur

Inscripziun en il register

Numer da publicaziun
EP4360621
Numer da la dumonda
EP23218288
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
En vigur
Scrittira da patent
Concedì
Annunzià
15-03-2013
Publitgà
01-05-2024
Concedì
06-05-2026
La protecziun finescha il pli tard
14-03-2033
Proxima taxa annuala scadenta
31-03-2027
Classas IPC
A61K 31/4184 (2006.01)
A61K 47/10 (2017.01)
A61K 9/00 (2006.01)
A61K 47/02 (2006.01)
A61K 47/20 (2006.01)
Prioritad
US 201261613173 P 20.03.2012
US 201261669889 P 10.07.2012
Derivà da
EP13764989
Lingua da l’annunzia
englais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 06-05-2026

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 06.05.2026

Partidas

Possessur

Eagle Pharmaceuticals, Inc.

50 Tice Boulevard Suite 315, Woodcliff Lake, NJ 07677, US

Inventur

SUNDARAM, Srikanth

Somerset, 08873, US

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.